Iovance Biotherapeutics Inc (STU:2LB)
€ 10.415 0.26 (2.56%) Market Cap: 3.20 Bil Enterprise Value: 2.89 Bil PE Ratio: 0 PB Ratio: 4.43 GF Score: 39/100

Iovance Biotherapeutics Inc at Barclays Global Healthcare Conference Transcript

Mar 15, 2023 / 05:35PM GMT
Release Date Price: €6.51 (+8.90%)
Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

Thank you. Good afternoon. Welcome to Barclays Global Healthcare Conference in Miami. And do e-mail myself or my colleagues if do you have any questions. And my name is Peter Lawson. I'm one of the U.S. biotech analyst that covers mid-cap oncology-related names at Barclays.

I'm really delighted to have on stage with me from Iovance, we've got Friedrich Finckenstein, Chief Medical Officer; and Igor Bilinsky, Chief Operating Officer.

Questions & Answers

Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

And maybe the first question for us, of course, everybody today probably and until the end of the month is just where you are for BLA filing? And how that process is if you're almost complete on -- what last steps are required?

Igor P. Bilinsky
Iovance Biotherapeutics, Inc. - COO

Thanks, Peter, and good afternoon, everyone. So we are on track to complete the BLA submission this quarter. We have

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot